# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce gene and cell-based therapies
- describe limitations of current therapies
- motivate need for non-invasive imaging
- introduce positron emission tomography (PET) reporter gene imaging
- describe conventional PET reporter gene systems
- discuss limitations of current PET reporter genes
- introduce human-gene derived PET reporter genes
- compare human-gene derived PET reporter genes
- discuss immunogenicity of viral PRGs
- motivate need for novel PET reporter gene systems
- summarize current state of PET reporter gene technology
- conclude need for novel PET reporter gene systems

## SUMMARY OF THE INVENTION

- introduce novel PET reporter gene systems
- describe non-immunogenic reporter genes
- introduce human mitochondrial thymidine kinase 2 (htk2) reporter gene
- describe enhanced htk2 reporter gene
- introduce novel PET/SPECT radiolabeled probes
- describe applications of novel PET reporter gene systems
- introduce safety gene function of htk2 reporter gene
- describe method for mutating htk2 gene
- introduce embodiments of the invention
- conclude summary of the invention

## DETAILED DESCRIPTION OF THE INVENTION

- define gene therapy and therapeutic genes
- define gene expression and monitoring
- motivate gene and cell-based therapies
- introduce PET reporter gene imaging
- describe PRG-PRP system
- introduce TK2-N93D/L109F mutant
- describe development of PET reporter gene systems
- introduce htk2 reporter gene system
- describe nucleic acid molecules encoding htk2 polypeptide
- introduce vectors comprising nucleic acid molecules
- describe host cells transfected with vectors
- introduce compositions of matter with non-naturally occurring thymidine analogs
- describe system for imaging mammalian cells using PET or SPECT
- introduce kit for imaging mammalian cells
- describe method of imaging mammalian cells using PET or SPECT
- introduce novel PET probes
- describe biodistribution of novel PET probes
- introduce ex vivo delivery of enhanced htk2 transgenes
- describe advantages of htk2 reporter genes
- describe applications of the present invention

## EXAMPLES

### Example 1

- introduce PET reporter probe systems
- describe PRG-PRP system components
- motivate L-[18F]FMAU and L-[18F]FEAU as PRPs
- summarize biodistribution studies in mice
- identify candidate PRGs
- evaluate TK2 as a PRG
- engineer N93D point mutation in TK2
- test TK2-N93D in cell culture and in vivo
- compare TK2, TK2-N93D, and HSV1-sr39tk in vivo
- evaluate L-[18F]FMAU and L-[18F]FEAU in L1210 tumor model
- describe Ad-liver model for evaluating PRG-PRP systems
- analyze potential immunogenicity of TK2-N93D PRG
- discuss potential caveats and alternative approaches
- conclude feasibility of the approach

### Example 2

- introduce preclinical studies
- describe cancer therapy models
- evaluate PRG-PRP systems in CRC model
- evaluate PRG-PRP systems in melanoma model
- discuss potential caveats and alternative approaches
- collaborate with other laboratories
- identify new TK2 mutants with improved catalytic activity

### Example 3

- introduce products for labeling and long-term cell-tracking PET studies
- develop and validate kits for PRG delivery
- produce PRG lentiviral delivery vectors
- develop PRG non-viral delivery vectors
- determine conversion factors to quantify in vivo TCs
- commercialize kits for preclinical animal model research
- establish service contracts for custom-prepared PRG-labeled TCs

### Example 4

- motivate eIND submission
- describe preclinical safety/toxicity studies
- outline dosimetry studies
- detail chemistry, manufacturing, controls and eIND submission
- discuss potential caveats and alternative approaches
- outline additional contingency plans

### Example 5

- introduce gene and cell based therapies
- describe method for evaluating PET reporter probes
- present results and conclusions

### Example 6

- introduce PET reporter gene imaging
- limitations of current cell/gene therapy trials
- motivation for non-invasive monitoring
- describe PET reporter gene imaging
- summarize existing PRGs
- limitations of HSV1-tk as PRG
- introduce human nucleoside kinases as PRGs
- describe dCK-double mutant and truncated TK2 PRGs
- motivate development of new PRG-PRP system
- describe development of TK2-N93D/L109F PRG
- describe biodistribution of L-18F-FMAU PRP
- describe enzyme engineering of TK2 mutant
- describe experimental procedures
- describe kinetic analyses of TK2-based candidate PRGs
- describe cell lines and probe uptake assays
- describe microPET/CT imaging studies in mice and human PET/CT studies
- introduce nucleoside analogs
- motivate use of L nucleosides as PET probes
- describe biodistribution of L-18F-FMAU and 18F-FHBG in mice
- compare biodistribution of L-18F-FMAU and 18F-FHBG
- motivate development of new PRG to be used with L-18F-FMAU
- describe structure of TK2 and its regulation by dTTP
- predict effect of N93D mutation on TK2 structure and function
- test effect of N93D mutation on TK2 activity
- describe cell-based uptake assays
- test effect of N93D mutation in vivo
- further improve selectivity and affinity of TK2-derived PRG for L-18F-FMAU
- describe homology model of TK2 with bound L-dT and D-dT
- identify additional mutations to improve selectivity of TK2 PRG for L analogs
- test effect of L109F mutation on TK2 activity
- generate and test TK2-N93D/L109F double mutant
- compare TK2-N93D/L109F with HSV1-sr39tk/18F-FHBG PRG-PRP systems
- determine biodistribution of L-18F-FMAU in humans
- discuss advantages of TK2-N93D/L109F/L-18F-FMAU PRG system
- discuss implications and future directions

### Example 7

- illustrate synthesis of L-18F-FMAU
- describe reaction conditions and procedures
- detail purification and characterization steps

### Example 8

- describe PET reporter gene probes
- evaluate probes based on conditions

